Patent portfolio with over 100 patents, issued and pending, protects expertise focusing on a $100 billion market alternative
Firm growing potential breakthrough two-fold expertise that may doubtlessly detect problematic neural alerts and ablate nerves in a single easy process for ache administration and different indications
THE WOODLANDS, TX, April 16, 2024 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Firm”), a medical gadget firm targeted on advancing progressive applied sciences to revolutionize how illnesses involving the nervous system are recognized and handled, as we speak introduced that the U.S. Patent and Trademark Workplace (USPTO) has issued U.S. patent 10,143,419 (‘419 patent) entitled “Programs and Strategies for Treating Most cancers and/or Augmenting Organ Operate.”
The issued patent is directed to expertise together with, however not restricted to, programs, strategies and units for interventionally treating cancerous tumors and most cancers associated ache. The Firm is initially advancing the event of its expertise to handle pancreatic cancer-related ache.
Lori Bisson, Chief Government Officer of Autonomix, commented, “The issuance of this U.S. patent represents a big milestone for the Firm and the continuing improvement of our doubtlessly breakthrough expertise. We place a excessive precedence on safety of our novel expertise and have invested in constructing a deep patent portfolio of 15 patent households with over 100 patents, issued and pending. We’re dedicated to advancing the event of our expertise with the aim of bringing nerve focused remedy to sufferers and imagine this patent additional validates the potential of our expertise. Along with our preliminary deal with the profitable completion of our first in man examine for pancreatic most cancers ache, a multi-billion greenback market alternative, we’re investigating extra makes use of for the expertise in different high-value indications with unmet wants.”
The Firm’s catheter-based sensing expertise is being developed to do two issues: sense neural alerts related to ache or illness and exactly goal these nerves for therapy. Autonomix believes this expertise is a greater various to the present approaches generally used as we speak, the place docs both depend on systemic medicine like opioids that lose effectiveness and have undesirable uncomfortable side effects or deal with suspected areas blindly in hopes of hitting the correct nerves, an strategy that’s usually inaccurate and might miss the goal and even trigger collateral injury to surrounding components of the physique.
The Firm is initially growing its expertise to handle pancreatic cancer-related ache. Present approaches, primarily counting on opioids or invasive ethanol injections, can present solely restricted reduction and will result in dangerous uncomfortable side effects. For extra details about the Firm’s expertise, please go to autonomix.com.
About Autonomix Medical, Inc.
Autonomix is a medical gadget firm targeted on advancing progressive applied sciences to revolutionize how illnesses involving the nervous system are recognized and handled. The Firm’s first-in-class expertise platform features a catheter-based microchip sensing array that has the flexibility to detect and differentiate neural alerts with roughly 3,000 instances better sensitivity than at the moment out there applied sciences. We imagine this may allow, for the primary time ever, transvascular analysis and therapy of illnesses involving the peripheral nervous system nearly anyplace within the physique.
We’re initially growing our expertise for pancreatic most cancers ache, a situation that may trigger debilitating ache and wishes an efficient answer. Nevertheless, our expertise constitutes a platform with the potential to handle dozens of indications, together with in cardiology, renal denervation and power ache administration throughout a large illness spectrum.
For extra info, go to autonomix.com and join with the Firm on X, LinkedIn, Instagram and Facebook.
Ahead Wanting Statements
A number of the statements on this launch are “forward-looking statements,” which contain dangers and uncertainties. Ahead trying statements on this press launch embody, with out limitation, the potential of the expertise to deal with hypertension and to finish its scientific examine in pancreatic most cancers ache. Such forward-looking statements will be recognized by way of phrases equivalent to ‘ought to,’ ‘could,’ ‘intends,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘tasks,’ ‘forecasts,’ ‘expects,’ ‘plans,’ and ‘proposes.’
Though Autonomix Medical, Inc. (or Autonomix) believes that the expectations mirrored in these forward-looking statements are based mostly on cheap assumptions, there are a variety of dangers and uncertainties that would trigger precise outcomes to vary materially from such forward-looking statements. You might be urged to rigorously assessment and take into account any cautionary statements and different disclosures, together with the statements made beneath the heading “Threat Components” and elsewhere within the providing round filed with the U.S. Securities and Alternate Fee (“SEC”) on January 26, 2024. Ahead-looking statements converse solely as of the date of the doc wherein they’re contained and Autonomix doesn’t undertake any responsibility to replace any forward-looking statements besides as could also be required by regulation.
Investor and Media Contact
JTC Workforce, LLC
Jenene Thomas
833-475-8247
autonomix@jtcir.com